GMED:NYE-Globus Medical Inc. Class A (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 66.5

Change

+0.24 (+0.36)%

Market Cap

USD 2.00B

Volume

0.87M

Analyst Target

USD 60.85
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Globus Medical Inc is a medical device company focused on developing products that promote healing in patients with musculoskeletal disorders. The Company also develops a robotic surgical navigation device and products to treat patients.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-21 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

+0.23 (+0.22%)

USD 179.96B
SYK Stryker Corporation

+1.96 (+0.57%)

USD 131.96B
BSX Boston Scientific Corp

-0.20 (-0.26%)

USD 113.42B
MDT Medtronic PLC

-0.62 (-0.76%)

USD 106.70B
EW Edwards Lifesciences Corp

-0.38 (-0.43%)

USD 52.43B
PHG Koninklijke Philips NV ADR

-0.22 (-0.85%)

USD 24.63B
STE STERIS plc

-2.76 (-1.25%)

USD 22.30B
ZBH Zimmer Biomet Holdings Inc

+0.22 (+0.21%)

USD 22.20B
SONVF Sonova Holding AG

N/A

USD 19.66B
SONVY Sonova Holding AG

-1.49 (-2.34%)

USD 19.16B

ETFs Containing GMED

CYBG:LSE VanEck Bionic Engineering.. 4.40 % 0.00 %

+0.06 (+0.37%)

USD 6.34M
EKG First Trust Nasdaq Lux Di.. 3.53 % 0.00 %

-0.11 (0.37%)

USD 2.39M
EASI 2.82 % 0.75 %

N/A

N/A
LSEQ Harbor Long-Short Equity .. 2.41 % 0.00 %

-0.08 (0.37%)

USD 0.01B
XHE SPDR® S&P Health Care Eq.. 1.96 % 0.35 %

-0.67 (0.37%)

USD 0.26B
HSMV First Trust Horizon Manag.. 0.00 % 0.00 %

-0.31 (0.37%)

USD 0.02B
GGEM:CA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 24.79% 81% B- 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.79% 81% B- 91% A-
Trailing 12 Months  
Capital Gain 21.55% 73% C 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.55% 70% C- 65% D
Trailing 5 Years  
Capital Gain 63.95% 68% D+ 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.95% 68% D+ 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 5.45% 44% F 59% D-
Dividend Return 5.45% 44% F 51% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.39% 74% C 43% F
Risk Adjusted Return 20.66% 53% F 42% F
Market Capitalization 2.00B 73% C 83% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.60 18% 5%
Price/Book Ratio 1.75 74% 47%
Price / Cash Flow Ratio 35.90 21% 6%
Price/Free Cash Flow Ratio 20.19 25% 14%
Management Effectiveness  
Return on Equity 2.28% 63% 33%
Return on Invested Capital 2.89% 55% 35%
Return on Assets 5.27% 88% 74%
Debt to Equity Ratio 10.44% 90% 87%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.